Evidence indicates that PPARγ agonists might have multiple beneficial effects in AD both on pathological processes in the brain and on peripheral factors such as serum glucose levels and insulin sensitivity that constitute potential risk factors for AD [171]. This evidence concerns the gene INS and Alzheimer disease.